ArticleThe oncologist2025
ALK-positive adult histiocytosis with a TFG-ALKfusion gene.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion.Cancer metastasis reviews · 2026Review
- Single-Site ALK-Positive Histiocytosis With TFG-ALK Fusion: Expanding the Clinical Spectrum of This Rare Entity.The American journal of case reports · 2026Article
- Laryngeal ALK Positive Histiocytosis: Potential Mimic of Inflammatory Myofibroblastic Tumor-Case Report and Literature Review.Head and neck pathology · 2026Review
- Oncofusions - shaping cancer care.The oncologist · 2025Article
- Juvenile xanthogranuloma of larynx and trachea, case report of a life-threatening condition.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
ALK-positive histiocytosis is a rare condition that can affect multiple systems in infants and adults. We identified a rare case of ALK-positive histiocytosis with fusion of the ALK gene with TFG. A 35-year-old previously healthy male has been complaining of back and hip discomfort for seven months. A radiologic examination of the spine and pelvis revealed several hypermetabolic osteolytic lesions. Immunostaining for LCA, CD68, CD117and ALK were positive, whereas immunostaining for CD1a, Langerin, and S100 were negative. Analysis with fluorescence in situ hybridization (FISH) confirmed the ALK rearrangements, and next-generation sequencing (NGS) revealed the fusion of the TFG and ALK genes. After receiving alectinib, an ALK inhibitor of the second generation, the patient showed a durable remission. ALK-positive histiocytosis is a distinct form of histiocytosis that has the potential to be treated with an ALK inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.